ProNAi Therapeutics, Inc. and Novosom Announce Collaboration to Enable Delivery of DNAi(R)-Based Cancer Therapeutics
KALAMAZOO, Mich. and HALLE, Germany--(BUSINESS WIRE)--ProNAi Therapeutics, Inc., a biopharmaceutical company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi®), today announced a collaboration with Novosom AG to enable successful delivery of DNAi®-based cancer therapeutics.